Blog

Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo

Amol Akhade/LinkedIn

May 8, 2025, 12:43

Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo

Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“Breaking News in HER2+ Early Breast Cancer.

Today, topline results from the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca & Daiichi Sankyo:

Neoadjuvant Enhertu (trastuzumab deruxtecan) and THP demonstrated a statistically significant & clinically meaningful improvement in pathological complete response (pCR) compared to standard ddAC and THP in patients with high-risk, locally advanced HER2+ early breast cancer.

First Phase 3 trial of Enhertu in early breast cancer.
High-risk HER2+ eBC population.
Early event-free survival (EFS) trend favoured Enhertu.

This could be a paradigm-shifting moment in the neoadjuvant space!”

Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo

More posts featuring Amol Akhade.

Amol Akhade AstraZeneca Breast Cancer cancer Daiichi Sankyo ddAC DESTINY-Breast11 Phase 3 fight against cancer Global fight against cancer HER2 MedOnc Neoadjuvant Enhertu OncoDaily Oncology Pathological complete response pCR Reliance Hospitals Suyog Cancer Clinics THP Trastuzumab deruxtecan

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking

Joe Biden Diagnosed with Aggressive Metastatic Prostate Cancer at Age 82